RA Capital Management Announces Close of $1.4 Billion Acquisition of Aliada Therapeutics by AbbVie [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
BOSTON Dec. 11, 2024 /PRNewswire/ -- RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today announced that AbbVie has closed its $1.4 billion acquisition of RA Capital's portfolio company Aliada Therapeutics. Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aß) antibody, which is in development for the treatment of Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier-crossing technology that enhances delivery of targeted drugs into the central nervous system. "Congratulations to the Aliada and AbbVie teams and our fellow investors on the close of this transaction," said Joshua Resnick , MD, Senior Managing Director at RA Capital Management and former board director at Aliada. "The acquisition of Aliada is the second significant acquisition
Show less
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing [Yahoo! Finance]Yahoo! Finance
- Chemotherapy Treatment Market Research Report 2024-2030: Advancements in Targeted Chemotherapy and Personalized Treatment Plan Developments Driving Growth [Yahoo! Finance]Yahoo! Finance
- Glaucoma Surgical Devices Market to Hit Valuation of US$ 1,546 Million by 2033 | Astute Analytica [Yahoo! Finance]Yahoo! Finance
- AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs [Yahoo! Finance]Yahoo! Finance
- Is AbbVie Stock a Buy? [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 10/30/24 - Beat
ABBV
Sec Filings
- 12/18/24 - Form 4
- 12/16/24 - Form 144
- 12/13/24 - Form 8-K
- ABBV's page on the SEC website